Your browser doesn't support javascript.
loading
Effects of Calcium Polystyrene Sulfonate Formulation Change from Dry Syrup to Oral Solution in Patients with Chronic Kidney Disease.
Kobayashi, Shunsuke; Ogawara, Yuka; Imamura, Yoshihiko; Kitaoka, Akira; Yasu, Takeo.
Afiliación
  • Kobayashi S; Department of Pharmacy, Nissan Tamagawa Hospital, Seta, Setagaya-ku, Tokyo, Japan. shunsukekobayashi0412@gmail.com.
  • Ogawara Y; Department of Pharmacy, Nissan Tamagawa Hospital, Seta, Setagaya-ku, Tokyo, Japan.
  • Imamura Y; Department of Nephrology, Nissan Tamagawa Hospital, Seta, Setagaya-ku, Tokyo, Japan.
  • Kitaoka A; Department of Pharmacy, Nissan Tamagawa Hospital, Seta, Setagaya-ku, Tokyo, Japan.
  • Yasu T; Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Kiyoseshi, Tokyo, Japan.
Int J Pharm Compd ; 26(5): 436-439, 2022.
Article en En | MEDLINE | ID: mdl-36053770
Calcium polystyrene sulfonate, a cation exchange resin preparation, is used to treat hyperkalaemia. The effects of switching from dry syrup to oral solution forms have been rarely evaluated. We investigated changes in serum potassium levels, incidence of adverse events, and patients' perception and satisfaction associated with the change in calcium polystyrene sulfonate dosage forms from dry syrup to oral solution in chronic kidney disease patients. The study population was comprised of 24 patients. The chronic kidney disease cause, glomerular filtration rate category, and albuminuria category was G4 in 10 cases (41.7%) and G5 in 8 cases (33.3%). No significant difference was observed between groups before and after the change in dosage form. Contrastingly, the ease of intake (P=0.0047), taste (P=0.0056), and satisfaction (P<0.001) indicated positive significant improvements. Changing the calcium polystyrene sulfonate dosage form from dry syrup to oral solution in patients with chronic kidney disease improved patient satisfaction while maintaining efficacy and safety. For patients in whom weight gain is not a problem, we recommend changing the dosage form from dry syrup to oral solution for calcium polystyrene sulfonate.
Asunto(s)
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Insuficiencia Renal Crónica / Hiperpotasemia Límite: Humans Idioma: En Revista: Int J Pharm Compd Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Insuficiencia Renal Crónica / Hiperpotasemia Límite: Humans Idioma: En Revista: Int J Pharm Compd Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos